Trial of Lixisenatide in Early Parkinson's Disease

Wassilios G Meissner¹, Philippe Remy¹, Caroline Giordana¹+42

• ¹From the French Clinical Research Network (F-CRIN) for Parkinson's Disease and Movement Disorders (NS-Park-F-CRIN) (W.G.M., P.R., C. Giordana, D.M., P. Derkinderen, J.-L.H., M.A., I.B., T.B., C.B.-C., N.C., O.C., J.-C.C., P. Damier, E.D., D.D., S.D., M.F., V.F., A.F.-S., S.F.-K., S.G., C.H., L.H., P.K., B.L., R.L., L.-L.M., A.M., C.M., F.O.-M., H.S., C. Thiriez, M.T., O.R.), Centre d'Investigation Clinique (CIC) 1436 and the Departments of Clinical Pharmacology and Neurosciences, Centre Expert Parkinson, University Hospital of Toulouse, INSERM, University of Toulouse 3 (C.B.-C., H.C., M.F., F.O.-M., C. Thalamas, O.R.), and CIC 1436, INSERM (E.D., A.S.), Toulouse, Service de Neurologie des Maladies Neurodégénératives, Centre Expert Parkinson, Institut des Maladies Neurodégénératives (IMN) Clinique (W.G.M., T.B., A.F.-S., B.L.), and Service d'Information Médicale, Unité de Soutien Méthodologique à la Recherche (USMR) (A.G., C. Germain, A.B.), Centre Hospitalier Universitaire (CHU) Bordeaux, Unité Mixte de Recherche (UMR) 5293, Université de Bordeaux, Centre National de la Recherche Scientifique (CNRS), IMN, Unité Mixte de Recherche (UMR) 5293 (W.G.M., T.B., A.F.-S.), and the European Clinical Trials Platform and Development-F-CRIN, CIC-Clinical Epidemiology Unit 1401, University of Bordeaux, INSERM, Institut Bergonié, CHU Bordeaux (A.G., C. Germain, A.B.), Bordeaux, the Department of Neurology, Centre Expert Parkinson, Equipe 01-Neuropsychologie Interventionnelle L'Institut Mondor de Recherches Biomédicales, CHU Henri Mondor, INSERM et Faculté de Santé, Université Paris-Est Créteil, Créteil (P.R., H.S.), the Department of Neurology, Centre Expert Parkinson, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice (C. Giordana, V.F., C.M.), the Department of Neurology, Centre Expert Parkinson, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, UMR 1239, Rouen University Hospital, University of Rouen, INSERM, Mont-Saint-Aignan (D.M.), and the Department of Neurology, Centre Expert Parkinson, Rouen University Hospital and University of Rouen (C.H., R.L.), Rouen, the Department of Neurology, Centre Expert Parkinson, CIC 1413, CHU Nantes, INSERM, Nantes (P. Derkinderen, P. Damier), Service de Neurologie, Centre Expert Parkinson, CIC 1402, CHU Limoges, CHU Poitiers INSERM, Limoges (J.-L.H., I.B., O.C.), the Department of Neurology, Centre Expert Parkinson, Strasbourg University Hospital, and Strasbourg Federation of Translational Medicine, Strasbourg University, Strasbourg (M.A.), the Institute of Genetics and Cellular and Molecular Biology, INSERM Unité 964, CNRS-UMR 7104, University of Strasbourg, Illkirch-Graffenstaden (M.A.), the Department of Medical Pharmacology INSERM Unité 1172, Lille Neurosciences and Cognition, Centre Hospitalier Régional Universitaire, University of Lille, Lille (N.C., D.D.), the Department of Neurology, CIC Neurosciences, Sorbonne Université, Paris Brain Institute, Assistance Publique-Hôpitaux de Paris, INSERM, CNRS, Pitié-Salpêtrière Hospital, Paris (J.-C.C., L.-L.M.), the Department of Neurology, Centre Expert Parkinson, CIC 1414, CHU Pontchaillou de Rennes, INSERM, Rennes (S.D.), the Department of Neurology, Centre Expert Parkinson, CHU de Nancy, Hôpital Central, Nancy (S.F.-K., L.H.), the Department of Neurology, Centre Expert Parkinson, University Hospital La Timone, Marseille (S.G.), the Department of Neurology, Centre Expert Parkinson, University Hospital of Amiens, Amiens (P.K., M.T.), the Department of Neurology, CHU Clermont-Ferrand, Université Clermont-Auvergne, CNRS, Image Guided Clinical Neuroscience and Connectomics, Institut Pascal, Clermont-Ferrand (A.M.), the Department of Nutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac (V.R.), and the Department of Neurology, Centre Expert Parkinson, CHU de Caen, Caen (C. Thiriez) - all in France; the Department of Medicine, University of Otago, Christchurch, and the New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.); Specialized Rehabilitation Hospital, Capital Health, Abu Dhabi, United Arab Emirates (P.K.); and Cure Parkinson's, London (S.R.W.S., R.K.W.).